Completed PHASE3 INTERVENTIONAL 1-arm NCT01802073

Primary Sclerosing Cholangitis With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects (PSC)

Treatment of Primary Sclerosing Cholangitis in Inflammatory Bowel Disease Patients With Oral Vancomycin by the Study of Its Antimicrobial and Immunomodulating Effects

Sponsor: Stanford University

Conditions Primary Sclerosing Cholangitis

Interventions Oral Vancomycin

Updated 8 times since 2017 Last updated: Aug 23, 2018 Started: Jan 31, 2012 Primary completion: Aug 31, 2015 Completion: Aug 31, 2015

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE3 trial investigates Primary Sclerosing Cholangitis and is currently completed. Stanford University leads this study, which shows 8 recorded versions since 2012 — indicating limited longitudinal coverage. The change history captured here reflects the iterative nature of clinical trial conduct.

Status Flow

Change History

8 versions recorded

Sep 2024 — Present [monthly]

Completed PHASE3
Jul 2024 — Sep 2024 [monthly]

Completed PHASE3
Jan 2021 — Jul 2024 [monthly]

Completed PHASE3
Oct 2018 — Jan 2021 [monthly]

Completed PHASE3

Status: Active Not Recruiting → Completed
Jun 2018 — Oct 2018 [monthly]

Active Not Recruiting PHASE3

▶ Show 3 earlier versions

Nov 2017 — Jun 2018 [monthly]

Active Not Recruiting PHASE3
Feb 2017 — Nov 2017 [monthly]

Active Not Recruiting PHASE3
Jan 2017 — Feb 2017 [monthly]

Active Not Recruiting PHASE3

First recorded

Jan 2012

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Stanford University

Data source: Stanford University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Palo Alto, United States